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1076-42 Subsets of CD8+ T Cells Are Expanded in Stable 
Coronary Artery Disease 
Lena Jonasson. Anders Wikby, Andrea Tompe, Research Center of Cardiovascular and 
Metabolic Diseases, Hdgland Hospital, Eksj6, Sweden, Department of Natural Sciences 
and Biomedicine, University College of Health Sciences, J6nk6ping, Sweden. 
Background: There is evidence for a systemic immune response, involving continuous 
T cell activation, in stable coronary artery disease (CAD). So far, the type of this T cell 
response is not fully understood. In this study we have examined certain phenotypical 
properties of CO8+ T cells in stable angina patients. 
Methods: Forty-four men (< 60 years of age) with stable angina and angiographically 
verified CAD were included as well as 70 healthy controls. T cell phenotypes in periph- 
eral blood were determined by 3 colour flow cytometry using triples of monoclonal anti- 
bodies against the following surface antigens and activation markers: CD3, CD4, CD8, 
CD57, CD28 and HLA-DR. 
Results: The total number of CD8+ cells did not differ significantly between patients and 
controls (577+~?.93 vs476 +~95 cells/mm3). However, the proportions of CD8+ ceils 
expressing HI.A-DR and CD57 were significantly increased in the patient group while the 
percentage of CD28-negative cells was decreased. Data are presented in the table. 
Conclusion: CD8+ cells are activated in patients with stable angina and there is an 
expansion of a certain CD8+ phenotype expressing CD57 but not CD28. This phenotype 
has been associated with suppressive activity and its role in stable CAD may be to con- 
trol an antigen-driven immune response. 
Patients Controls p 
CD57+ CDS+ 
cells/mm 3 317+_234 220_+258 0.04 
% of total CDS+ 47 37 0.005 
CD28- CD8+ 
cells/mm 3 363+~?.64 262_+282 0.06 
% of total CO8+ 52 45 0.05 
HLA-DR+ CD8+ 
cells/mm 3 159-+111 101 _+73 0.003 
% of total CD8+ 25 20 0.01 
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801-2 Impact of New Diagnostic Criteria for Myocardial 
Infarction in an Unselected United Kingdom Cohort 
With Suspected Cardiac Chest Pain 
Jasoer Trevelvan, Shane Gieowarsingh, Mauro Lencioni, Edward W. Needham, Stehpen 
C. Smith, Raj K. Mattu, University Hospitals of Coventry and Warwickshire, Covent~ 
United Kingdom. 
Background: The Joint European Society of Cardiology/American College of Cardiology 
Committee's revised definition of myocardial infarction (MI) proposes the primacy of the 
cardiac troponins in the diagnosis of MI, with CK-MB a recommended alternative. These 
recommendations may increase the incidence of MI and reduce case fatality, but this has 
not been examined prospectively. We therefore assessed the diagnostic impact of these 
changes in an unselected UK cohort with suspected cardiac chest pain 
Methods: We enrolled all patients admitted with suspected cardiac chest pain over 6 
months, with usual care provided by the attending physician with serial ECGs and creat- 
ine kinase (CK)/aspartate transaminase (AST). Additional blinded measurements of CK- 
MB mass and troponin T (cTnT) were made. After discharge a blinded panel reviewed 
the case notes and reached a World Health Organisation diagnosis utilising electrocar- 
diograms/CK/AST, a CK-MB diagnosis using CK-MB as the gold-standard cardiac 
marker at 2 discriminator values (5 and 10mg/L), and a cTnT diagnosis in accordance 
with the new recommendations. 
Results: 401 patients were enrolled. In comparison to the WHO diagnosis, CK-MB at 
5mg/L diagnosed a further 23.2% (36 of 155) MIs, 11 patients with high risk unstable 
angina pectoris (UAP) and excluded MI in 4 patients, with overall 51 (12.7%) patients 
having a significant diagnostic adjustment. At 10rag/L, CK-MB diagnosed 126 patients as 
MI, 35 as high risk UAP, with a diagnostic alteration in 54 (13.5%) patients. The revised 
criteria utilising cTnT diagnosed a further 26.1% (42 of 161) MIs, and excluded MI in 4 
patients, with 1t.5% of patients having a significant diagnostic alteration. Sedal CK and 
AST measurements had a diagnostic sensitivity of 70.5% and 69.0% respectively for MI. 
Conclusion: Introduction of the revised diagnostic criteria for MI diagnoses an additional 
26.1% of patients with MI. CK-MB diagnoses a broadly similar cohort as MI at a lower 
discriminator value, but not at the higher threshold. Serial CK/AST and ECGs mis-diag- 
nose 11.5% of all chest pain admissions when compared with the new definition for MI. 
9:45 a.m. 
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801 Diagnosis and Natural History of Acute 
Coronary Syndromes  
Monday, March 18, 2002, 9:15 a.m.-lO:ao a.m. 
Georgia World Congress Center, Room 264W 
9:15 a.m. 
801-1 Six-Month Prognosis of Patients Diagnosed With 
Myocardial Infarction by World Health Organization 
Criteria Versus New European Society Cardiology/ 
American College Cardiology Troponin-Based Criteria 
Jasoer Trevelvan. Mauro Lencioni, Shane Gieowarsingh, Edward W. Needham, Stephen 
C. Smith, Raj K. Mattu, University Hospitals of Coventry and Warwickshire, Covent~ 
United Kingdom. 
Background: The Joint European Society of Cardiology/American College of Cardiology 
Committee's revised definition of myocardial infarction (MI) proposes the primacy of the 
cardiac troponins in the diagnosis of MI. The committee state that these changes will 
reduce fatality, but this has never been tested prospectively. We assessed the prognosis 
of patients diagnosed as MI by the new versus World Health Organisation (WHO) criteria 
over 6 months. 
Methods: All patients admitted with suspected cardiac chest pain were enrolled. A 
blinded panel reached a WHO diagnosis utilising serial electrocardiograms/creatine 
kinase/aspartate transaminase, and a troponin T (cTnT) diagnosis in accordance with the 
new criteria. 6 month major adverse cardiovascular events (MACE) were recorded 
(table). Kaplan-Meier survival analysis was performed by time to first event. 
Results: 401 patients were enrolled. 161 patients had a cTnT MI, with 42 of these being 
WHO negative. All MACE events apart from CABG were more common in cTnT positive 
patients, irrespective of WHO status. 
cTnT/WHO cTnT positive / WHO cTnT negative 
positive (n=119) negative (n=42) (n=240) 
Cardiac Death 8 (6.7%) 5 (11.9%) 3 (1.3%) (p=O.001) 
Non-fatal MI 9 (7.6%) 0 (0.0%) 0 (0.0%) (p<O.0001) 
PTCA 11 (9.2%) 4 (9.5%) 0 (0.0%) (p<0.0001) 
CABG 4 (3.4%) 3 (7.1%) 9 (3.8%) (p=ns) 
Readmission UAP 17 (14.3%) 6 (14.3%) 10 (4.2%) (p=O.001) 
Any MACE 32 (26.9%) 12 (28.6%) 17 (7.1%) (p<O.O001) 
Kaplan-Meier analysis demonstrates that the cTnT positive groups display almost identi- 
cal MACE-free survival, significantly inferior to cTnT negative patients (log rank Z 2 31.86, 
p<O.O0001 ).
Conclusion: cTnT positive /WHO negative patients have a similar prognosis to cTnT/ 
WHO positive patients. Troponin negative patients have a superior, but not entirely 
benign, prognosis. 
801-3 Validation of ACC-AHA 2000 Guidelines for the Risk 
Stratification of Patients With Non-ST Elevation Acute 
Coronary Syndromes 
Oscar Bazzino. Fernando Botto, Jos~ L. Navarro Estrada, Maria i. Sosa Liprandi, Juan J. 
Fuselli, Jos~ Santopinto, Rodolfo Ahuad, Roberto Nordaby, Simon Salzsberg, Alfredo 
Hirschson Prado, Jos~ Gant L6pez, Mario Russo, Marcelo Perez, Cados Bruno, Raul De 
Miguel, PACS Investigators, Buenos Aires, Argentina. 
Background: New recommendations have been recently developed regarding the risk 
stratification of non ST elevation acute coronary syndromes. We compared the preva- 
lence and prognostic value of new (2000) and past (t994) risk categories. Methods: This 
prospective multicenter cohort study included 1000 consecutive patientes admitted to 
CCU because of non-ST-elevation acute coronay syndromes. Baseline clinical and elec- 
trocardiographic data were recorded. Single assays of 3rd generation troponin T was 
performed after a median time of 9 hours from sympton onset. The primary endpoint was 
the 180-day incidence of the composite of death or myocardial infarction (D/AMI). 
Results: D/AMI occurred in 9.4% of patients at 180days. Event rates according to past 
and new guidelines are shown: 
Year 2000 Year 1994 
n ER% OR 95%CI p n ER% OR 95%CI p 
LR 78 1.3 0.11 0.01-0.83 0.005 52 1.9 0.17 0.02-1.30 0.053 
MR 273 6.2 0.55 0.32-0.95 0.03 537 8.4 0.75 0.49-1.10 0.19 
HR 649 11.9 2.50 1.41-4.23 0.0001 411 11.9 1.60 1.00-2.40 0.037 
ER: event rate, LR: low risk, MR: medium risk, HR: high risk, OR: odds ratio 
Receiver operating curves were 0.60+0.03 and 0.56+0.32 (p=NS), for the new and old 
classifications respectively. The new guidelines evidenced higher sensitivity (81% vs 
51%), and less specificity (37% vs 60%), with similar positive and negative predictive val- 
ues: 12% vs 12% and 95% vs 92%, respectively. Conclusions: An important conse- 
quence of the present guidelines is an increase of the high risk group, with a proportional 
reduction in the size of the medium risk group. The new guidelines are more sensitive 
and identified more hard events than the older reccomendations. 
10:00 a.m. 
801-4 A Simple Risk Score for Prediction of 30-Day Morta l i ty  
in Patients With Acute Coronary Syndrome: Insights 
From GUSTO IV 
W.H. Wilson Tano. H/tinder S. Gurm, Marion Piedmonte, Elliot S. Barnathan, Judith 
Cooper, Robert M. Califl, Eric J. Topoi, Cleveland Clinic Foundation, Cleveland, Ohio. 
Background: Acute coronary syndrome (ACS) is a common illness with a significant 
early risk of death. A simple clinical risk score can provide a valuable tool for physicians 
in prognostication and better focusing of therapy in the more at-risk population. Previ- 
ously described risk scores have been derived from smaller populations thus limiting a 
wider application. 
Methods: We examined a total of 27 factors that were easily available at the initial bed- 
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side evaluation as potential predictors of death in the 7,796 subjects enrolled in the 
GUSTO IV tdal with 301 deaths at 30 days (3.86%). Univariate logistic regression models 
were fit to the data and then multivariate logistic regression models were developed and 
creating a simplified scoring system using the Hosmer-Lemeshow goodness of fit statis- 
tics and c-index. The predictive accuracy of the multivadable model was assessed using 
bootstrap methods. 
Results: The final multivariate model included age (2 points plus additional 2 points for 
every decade above 50), 4 major criteria (history of heart failure, stroke/transient 
ischemic attacks, renal insufficiency or elevated CK-MB - each 2 points) and 6 minor pre- 
dictors (elevated troponin and C-reactive protein, ST depression, anemia, hypercholes- 
terolemia and history of coronary disease - each 1 point). Thirty-day mortality increased 
significantly with a dsing score (0.29% for 0-4 points, 1.75 % for 5-9 points; 7.17% for 11- 
14 points, 24% for >15 points). This model provides a robust risk scoring system with a c- 
index of 0.797 (range from 0.744 to 0.841 using bootstrap methods, compared to 0.56 in 
the TIMI risk score for 14-day mortality). In the final multivariate model, traditional risk 
factors such as male gender, diabetes mellitus, hypertension, prior aspidn use, recent 
angina and current smoking history has little effect on the model performance in predict- 
ing 30-day mortality. 
Conclusion: The GUSTO risk score provides a simple and easy-to-use risk scoring sys- 
tem that incorporates multiple factors in predicting 30-day risk of death in patients pre- 
senting with ACS. This risk score illustrates the importance of age and comorbid 
conditions in the process of risk stratification. 
10:15 a.m. 
801-5 One-Year  Fo l low-Up o f  Morta l i ty  in the GUSTO IV Trial 
Evaluating the Effects of 24 - 48 Hours Abciximab 
Infusion in Noninvaeively Managed Acute Coronary 
Syndrome Patients 
Msarten Simoons. Paul Armstrong, Elliot Barnathane, Robert Califf, Stefan James, Eric 
Topoi, Lars Wallentin, the GUSTO-IV ACS trialists, Department of cardiology, Rotterdam, 
The Netherlands, Thoraxcanter, Uppsala, Sweden. 
Background: The long-term efficacy of abciximab (Abx) treatment is proven in acute cor- 
onary syndrome (ACS) patients undergoing eady revascularisation. However, as medical 
treatment in primarily noninvasively managed patients, Abx did not provide any advan- 
tages compared to placebo in the GUSTO IV trial. We now present the 1-year follow-up. 
Methods: The multinational prospective doubts-blind trial of the efficacy of abciximab as 
the pdmary medical treatment in ACS without early revasculadzation. The trial included 
7800 patients with chest pain within 24 hours and either ST-segment depression or ele- 
vation of treponin at entry. The patients were randomized to bolus injection followed by 
24 hours (n=2590) or 48 hour (n=2612) infusion of Abx or corresponding placebo 
(n=2598) in addition to heparin and aspidn. At 30 days follow up there were no differ- 
ences between the groups regarding deaths and/or myocardial infarctions. Information 
on mortality was collected after 1 year. Pre-specified subgroups were (amongst others) 
gender and body-weight. 
Results: Mortality at one year: 
*No statistical differences between groups 
Conclusion: At one year there was no difference in mortality between the randomized 
treatment groups. However in the abciximab 46 hours group there was a trend for a 
higher mortality compared to placebo. In the subgroup with body weight below 75 kg 
there was a significant increased mortality. This might indicate possible dose-related 
harmful effects of abciximab at long-term infusion. 
Mortality at one year 
Placebo Abx 24 h Abx 48 h Abx 24+48 h 
Total mortality 7.8% (203) 8.2% (212) 9.0% (234) 8.6% (446) 
p-values vs placebo 0.62 0.14 0.25 
Males* 7.7% (124) 7.4% (118) 8.6% (143) 8.0% (261) 
Females* 8.0% (79) 9.4% (84) 9.6% (91) 9.5% (185) 
<75 kg 8.6% (107) 8.9% 115) 11.4% (142) 10.1% (257) 
p-values vs placebo ns 0.02 0.13 
>75 kg 7.t% (57) 8.1% (65) 7.0% (61) 7.5% (126) 
p-values vs placebo ns ns ns 
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804 New Approaches to Coronary Bypass 
Surgery 
Monday, March 18, 2002, 9:15 a.m.-10:30 a.m. 
Georgia World Congress Center, Room 254W 
9:15 a.m. 
804-1 Cl in ica l  Benefits of Glucose-Insulin-Potassium Infusion 
in Coronary  Ar tery  Bypass Grafting: Is Improved 
Diastolic Function the Mechanism? 
Michael W. Tsaqg, Ravin Davidoff, J. Frederick Hesselvik, Hao Nguyen, Oz M. Shapira, 
Boston Medics~ Center, Boston, Massachusetts. 
Background: Glucose-Insulin-Potassium (GIK) infusion improves clinical outcome post 
CABG. The mechanism of benefit is unclear, but GIK limits ischemia and reperfusion 
injury. This study was designed to assess whether the benefit of GIK is mediated through 
a reduction in the degree of diastolic dysfunction that occurs post CABG. 
Methods: 31 patients undergoing CABG were randomized to GIK vs no GIK. LV compli- 
ance, using pressure-area relationships, was assessed by simultaneous TEE measure- 
ment of LV end-diastolic area (LVEDA) and pulmonary capillary wedge pressure (PCWP) 
at baseline, post cardiopulmonary bypass (CPB), and serially up to 3 hours post-op. 
LVEDA was measured at a constant PCWP, thus a decrease in LVEDA reflects a leftward 
shift in the pressure-area relationship consistent with decreased compliance. 
Results: Both groups demonstrated universal and progressive worsening of LV compli- 
ance. Transmittal E wave deceleration time decreased consistent with restrictive LV fill- 
ing. GIK did not alter either measure of diastolic function significantly. 
Conclusion: Diastolic dysfunction occurs nearly universally after CPB, worsens with 
chest closure, persists for up to 3 hours into the postoperative period, and is unaffected 
by GIK. This confirms that diastolic dysfunction post CABG is a result of both myocardial 
and mechanical factors. Despite theoretical reasons why GIK might limit ischemic injury, 
clinical benefits do not appear to be related to amelioration of diastolic dysfunction. 
*No statistically significant difference between the 2 groups 
LVEDA (om 2) Baseline Off CPB Chest Closed 3 Hour =)-value (trend~ 
NoGIK 17.5+4.6 15.7_+4.2 15.0_+3.2 14.3_+3.5 <0.001 
GIK * 16.3+2.8 14.9_+2.8 14.2_+2.4 13.8_+2.9 <0.001 
E Decel (sec) 
No GIK 0.21+.05 0.20_+.04 0.18_+.03 0.17_+.04 0.002 
GIK * 0.23+.04 0.21-+.04 0.20-+.04 0.18_+.05 0.0017 
9:30 a.m. 
804-2 Is V i tamin  C Super io r  to  Di l t iazem for  Radia l  Ar tery  
Vasodilation in Patients Awaiting Coronary Artery 
Bypass Grafting? A Randomized Double Blind Study 
George E. Drossos, Ioannis K. Toumpoulis, Demosthenes G. Katdtsis, John P. Ioannidis, 
Persephone Kontogiorgi, Eugenia Svama, Stavros Siminelakis, Constantine I~, 
Anaanostoooulo~, University of Ioannina School of Medicine, Ioannina, Greece, St 
Luke's~Roosevelt Hospita/ Center at Co/umbia Univerei~ New York, New York. 
Background The perioperative use of a vasodilator appears to be important in assuring 
the success of radial artery conduits. Vitamin C (vit C) has been shown to reverse endot- 
helial dysfunction in smokers and patients with coronary artery disease (CAD) or other 
predisposing factors. It is not known whether vitamin C could be used instead of calcium 
channel blockers as a vasodilator in coronary patients receiving radial artery conduits. 
Methods In a case-control study (study I), oral single-dose vit C (2g) was given to 15 
healthy non-smokers and 15 matched healthy smokers. In a randomized, double blind 
study (study II), oral single-dose vit C (2g) (n=15) and diltiazem (180mg) (n=15) were 
compared in preoperative patients with CAD. We examined the flow-mediated dilation 
with high-resolution ultrasound and color Doppler images and measurement of the lumen 
surface of the non-dominant radial artery just before and two hours after drug administra- 
tion. 
Results In study I, both smokers and non-smokers showed a significant increase in 
lumen surface at 2 hours compared with baseline (p<0.001 and p=0.013, respectively). 
This was larger in smokers (median 37.5% vs. 14.3%, p=0.004). In study II, both groups 
showed significant increases in lumen surface at 2 hours compared with baseline values 
(p<O.001 and p=0.008 for vit C and diltiazem, respectively). Vit C achieved a larger 
increase than diltiazem (median 33.3% vs. 18.2%, p=0.016), in multivariate modeling, 
the increase in lumen surface was independently predicted by use of vit C over diltiazem 
(+21.2%, p=0.007), diabetes menitus (+14.5%, p=0.085), elevated cholesterol (+26.2%, 
p=0.001) and smoking history (+20.8%, p=0.017). 
Conclusions Vit C is a potent acute vasodilator in both smokers and non-smokers. In 
patients awaiting coronary artery bypass grafting, an oral dose of vitamin C results in 
greater vasodilation of the radial artery within 2 hours, as compared with an oral dose ot 
diltiazem. 
